Minor editorials?? They challenged the validity of the clinical trial conclusions.
Did you read the conflict-of-interest statement in the JAMA Oncology article?? Many of the clinicians also participated in NVCR trials. among other major oncology companies.
The issues raised by the critics are significant and regulators will easily see the same issues. That increases the odds that NWBO's application will be rejected. Note NWBO isn't making plans for commercialization of DCVax-L -- no commercial head, no plans for a sales organization, etc. That's pretty abnormal for a biotech.
Market Data 
Markets 
AI
